# SI-BONE, Inc.: overview

SIBN · Nasdaq · CIK 1459839 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sibn.md) · [Financials](/companies/sibn/financials.md) · [Filings](/companies/sibn/filings.md) · [Insiders](/companies/sibn/insiders.md)

Latest reported revenue: [$56.0m](/filings/0001459839-26-000069.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001459839-26-000069).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [40.3](/filings/0001459839-25-000095.md) | [49.0 d](/filings/0001459839-26-000036.md) | [47.3](/filings/0001459839-26-000056.md) | [48.6](/filings/0001459839-26-000069.md) | [48.7](/filings/0001459839-25-000095.md) | [56.3 d](/filings/0001459839-26-000036.md) | [52.6](/filings/0001459839-26-000056.md) | [56.0](/filings/0001459839-26-000069.md) |
| Gross margin | % | [79.1%](/filings/0001459839-25-000095.md) | [79.1% d](/filings/0001459839-26-000036.md) | [79.7%](/filings/0001459839-26-000056.md) | [79.8%](/filings/0001459839-26-000069.md) | [79.8%](/filings/0001459839-25-000095.md) | [79.0% d](/filings/0001459839-26-000036.md) | [79.8%](/filings/0001459839-26-000056.md) | [79.5%](/filings/0001459839-26-000069.md) |
| Operating margin | % | [(18.9%)](/filings/0001459839-25-000095.md) | [(11.2%) d](/filings/0001459839-26-000036.md) | [(15.8%)](/filings/0001459839-26-000056.md) | [(14.4%)](/filings/0001459839-26-000069.md) | [(11.1%)](/filings/0001459839-25-000095.md) | [(4.4%) d](/filings/0001459839-26-000036.md) | [(9.7%)](/filings/0001459839-26-000056.md) | [(8.6%)](/filings/0001459839-26-000069.md) |
| Net margin | % | [(16.3%)](/filings/0001459839-25-000095.md) | [(9.2%) d](/filings/0001459839-26-000036.md) | [(13.8%)](/filings/0001459839-26-000069.md) | [(12.7%)](/filings/0001459839-26-000069.md) | [(9.4%)](/filings/0001459839-25-000095.md) | [(2.9%) d](/filings/0001459839-26-000036.md) | [(8.2%)](/filings/0001459839-26-000069.md) | [(7.3%)](/filings/0001459839-26-000069.md) |
| Diluted EPS | $ per share | [(0.16)](/filings/0001459839-25-000095.md) | not reported | [(0.15)](/filings/0001459839-26-000056.md) | [(0.14)](/filings/0001459839-26-000069.md) | [(0.11)](/filings/0001459839-25-000095.md) | not reported | [(0.10)](/filings/0001459839-26-000056.md) | [(0.09)](/filings/0001459839-26-000069.md) |
| Free cash flow | $m | [(2.7) d](/filings/0001459839-25-000095.md) | [(1.1) d](/filings/0001459839-26-000036.md) | [(7.0)](/filings/0001459839-26-000056.md) | [(1.9) d](/filings/0001459839-26-000069.md) | [(0.6) d](/filings/0001459839-25-000095.md) | [0.4 d](/filings/0001459839-26-000036.md) | [(3.4)](/filings/0001459839-26-000056.md) | [(0.8) d](/filings/0001459839-26-000069.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [90.2](/filings/0001459839-23-000020.md) | [106](/filings/0001459839-25-000036.md) | [139](/filings/0001459839-26-000036.md) | [167](/filings/0001459839-26-000036.md) | [201](/filings/0001459839-26-000036.md) |
| Gross margin | % | [88.4%](/filings/0001459839-23-000020.md) | [85.2%](/filings/0001459839-25-000036.md) | [78.8%](/filings/0001459839-26-000036.md) | [79.0%](/filings/0001459839-26-000036.md) | [79.6%](/filings/0001459839-26-000036.md) |
| Operating margin | % | [(57.3%)](/filings/0001459839-23-000020.md) | [(56.0%)](/filings/0001459839-25-000036.md) | [(33.8%)](/filings/0001459839-26-000036.md) | [(21.1%)](/filings/0001459839-26-000036.md) | [(11.1%)](/filings/0001459839-26-000036.md) |
| Net margin | % | [(62.8%)](/filings/0001459839-23-000020.md) | [(57.6%)](/filings/0001459839-25-000036.md) | [(31.2%)](/filings/0001459839-26-000036.md) | [(18.5%)](/filings/0001459839-26-000036.md) | [(9.4%)](/filings/0001459839-26-000036.md) |
| Diluted EPS | $ per share | [(1.71)](/filings/0001459839-23-000020.md) | [(1.79)](/filings/0001459839-25-000036.md) | [(1.13)](/filings/0001459839-26-000036.md) | [(0.75)](/filings/0001459839-26-000036.md) | [(0.44)](/filings/0001459839-26-000036.md) |
| Free cash flow | $m | [(45.9)](/filings/0001459839-23-000020.md) | [(51.2)](/filings/0001459839-25-000036.md) | [(26.5)](/filings/0001459839-26-000036.md) | [(22.9)](/filings/0001459839-26-000036.md) | [(9.1)](/filings/0001459839-26-000036.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sibn/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [First Light Asset Management, LLC](/funds/1600004.md) | 2026-06-30 | $132.6m | 8,127,985 |  | Added +2,774,795 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $60.0m | 3,676,259 |  | Added +247,718 |
| [CADIAN CAPITAL MANAGEMENT, LP](/funds/1423686.md) | 2026-06-30 | $54.6m | 3,347,574 |  | Added +1,460,102 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $41.0m | 2,510,963 |  | Added +1,898 |
| [BROWN ADVISORY INC](/funds/1345929.md) | 2026-06-30 | $33.9m | 2,077,134 |  | Reduced −45,198 |
| [Granahan Investment Management, LLC](/funds/1026710.md) | 2026-06-30 | $31.5m | 1,931,182 |  | Added +192,085 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $30.0m | 1,838,499 |  | Added +74,186 |
| [Impax Asset Management Group plc](/funds/1749768.md) | 2026-06-30 | $23.3m | 1,425,010 |  | Unchanged |
| [GILDER GAGNON HOWE & CO LLC](/funds/902464.md) | 2026-06-30 | $20.4m | 1,253,042 |  | Added +204,526 |
| [PARADIGM CAPITAL MANAGEMENT INC/NY](/funds/1037792.md) | 2026-06-30 | $20.1m | 1,233,200 |  | Added +106,700 |

## Recent filings

[All 771 filings](/companies/sibn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-11 | 16:05 ET | [8-K](/filings/0001459839-26-000076.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001459839-26-000076 |
| 2026-08-04 | 16:13 ET | [10-Q](/filings/0001459839-26-000069.md) | Quarterly report, period 2026-06-30 | 0001459839-26-000069 |
| 2026-08-03 | 16:11 ET | [8-K](/filings/0001459839-26-000066.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001459839-26-000066 |
| 2026-06-08 | 16:09 ET | [8-K](/filings/0001459839-26-000059.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001459839-26-000059 |
| 2026-05-11 | 17:03 ET | [10-Q](/filings/0001459839-26-000056.md) | Quarterly report, period 2026-03-31 | 0001459839-26-000056 |
| 2026-05-11 | 16:11 ET | [8-K](/filings/0001459839-26-000054.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001459839-26-000054 |
| 2026-04-21 | 16:10 ET | [DEF 14A](/filings/0001459839-26-000049.md) | Proxy statement, period 2025-12-31 | 0001459839-26-000049 |
| 2026-02-24 | 16:19 ET | [10-K](/filings/0001459839-26-000036.md) | Annual report, period 2025-12-31 | 0001459839-26-000036 |
| 2026-02-23 | 16:11 ET | [8-K](/filings/0001459839-26-000022.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 5.02 Departure or appointment of officers or directors | 0001459839-26-000022 |
| 2026-01-12 | 09:11 ET | [8-K](/filings/0001459839-26-000010.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001459839-26-000010 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001459839-26-000036.md), filed Feb 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ef44e99b-6f82-45eb-8e00-49222cdeb46f)

## About the filer

- CIK: 1459839
- Tickers: SIBN
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:22 ET. No prices; not investment advice.